Company News: Mylan, Schering, MSP Singapore, Novartis and Corthera

Share this article:
Generics firm Mylan said it filed an ANDA application with the FDA to market copycat versions of Merck cholesterol drug Vytorin and that it may be the first company to do so. The firm also said it has been sued by Schering and MSP Singapore in connection with the Vytorin filing. The lawsuit triggers a 30-month stay on approval until first quarter 2012. If Mylan's ANDA is the first, the submission would qualify the company for 180 days of marketing exclusivity. Collins Stewart analyst Louise Chen estimated an exclusive generic launch of Vytorin could bring in $100 million in sales. For the year ending last September, Vytorin tablets posted about $1.6 billion in sales for the same four strengths included in Mylan's application, said the company citing IMS Health figures. Vytorin combines cholesterol-reducing agents ezetimibe and simvastatin.

Novartis said it is buying Corthera, a privately held US biopharma company, for $120 million and gaining rights to Phase-III heart-failure treatment Relaxin. Corthera shareholders are eligibile for additional milestone payments of up to $500 million. Novartis hopes to file Relaxin for US and European marketing approval in 2013. Separately, the Swiss company is likely to increase its stake in eyecare company Alcon, various news outlets reported. Novartis owns a 25% stake in Alcon, purchased last year from Nestle for $11 billion, and an option to buy 52% more starting next month. Nestle can also push Novartis to buy the 52%. Analysts said the deal seems likely to occur soon after the New Year, ever since Alcon's share price rose above a threshold where it makes sense for both sides. If the second step goes through, Novartis is expected to pay about $28 billion for Nestle's remaining stake.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders

Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.